Abstract
Bisphosphonates (BPs) are widely used for the treatment of a range of conditions involving bone, such as osteoporosis and bone metastases of cancer, and their efficacy has been confirmed. Nevertheless, a first case of bisphosphonate- related osteonecrosis of the jaw (BRONJ) as an adverse effect of BP treatment was reported in 2003, and several clinical studies since then have elaborated the risk, prevention and treatment of BRONJ or bisphosphonate-related osteomyelitis of the jaw (BROMJ). However, effective decision making on BP risk is hampered by a lack of accurate information for patients, physicians or dentists. Furthermore, the narrow definition of BRONJ used to date has precluded the wider development of clinical research on risk.
In this review, we discuss current issues in BROMJ, with a focus on risk, prevention and treatment. In particular, we reconsider the definition of BRONJ from the standpoint of clinical evidence. Finally, we propose a new strategy for the treatment of BROMJ.
Keywords: Absolute risk, bisphosphonate, osteonecrosis of the jaw, prevention, prognosis, relative risk, risk factors, treatment.
Reviews on Recent Clinical Trials
Title:Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment
Volume: 9 Issue: 1
Author(s): Toru Yamazaki, Katsu Takahashi and Kazuhisa Bessho
Affiliation:
Keywords: Absolute risk, bisphosphonate, osteonecrosis of the jaw, prevention, prognosis, relative risk, risk factors, treatment.
Abstract: Bisphosphonates (BPs) are widely used for the treatment of a range of conditions involving bone, such as osteoporosis and bone metastases of cancer, and their efficacy has been confirmed. Nevertheless, a first case of bisphosphonate- related osteonecrosis of the jaw (BRONJ) as an adverse effect of BP treatment was reported in 2003, and several clinical studies since then have elaborated the risk, prevention and treatment of BRONJ or bisphosphonate-related osteomyelitis of the jaw (BROMJ). However, effective decision making on BP risk is hampered by a lack of accurate information for patients, physicians or dentists. Furthermore, the narrow definition of BRONJ used to date has precluded the wider development of clinical research on risk.
In this review, we discuss current issues in BROMJ, with a focus on risk, prevention and treatment. In particular, we reconsider the definition of BRONJ from the standpoint of clinical evidence. Finally, we propose a new strategy for the treatment of BROMJ.
Export Options
About this article
Cite this article as:
Yamazaki Toru, Takahashi Katsu and Bessho Kazuhisa, Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment, Reviews on Recent Clinical Trials 2014; 9 (1) . https://dx.doi.org/10.2174/1574887109666140423120614
DOI https://dx.doi.org/10.2174/1574887109666140423120614 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Angiogenesis-Related Proteins - Their Role in the Pathogenesis and Treatment of Inflammatory Bowel Disease
Current Protein & Peptide Science Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils
Anti-Cancer Agents in Medicinal Chemistry Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry Lymphatics and Inflammation
Current Medicinal Chemistry Intracellular Logistics of BST-2/Tetherin
Current HIV Research Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy